Iclusig Unión Europea - español - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. ver secciones 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

ICLUSIG® 15mg Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

iclusig® 15mg

takeda pharmaceuticals company limited japon - ponatinib 15.0 mg - tableta recubierta - cada tableta recubierta contiene: ponatinib 15.0 mg (agregada como ponatinib hcl) (a)

NIBCLUS 45MG Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

nibclus 45mg

laboratorio varifarma s.a. argentina - cada comprimido recubierto contiene: ponatinib 45 mg (como ponatinib clorhidrato 48,1 mg). - comprimidos recubiertos - cada comprimido recubierto contiene: ponatinib 45 mg (como ponatinib clorhidrato 48,1 mg).

NIBCLUS 15MG Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

nibclus 15mg

laboratorio varifarma s.a. argentina - cada comprimido recubierto contiene: ponatinib 15 mg (como ponatinib clorhidrato 16.03 mg) - comprimidos recubiertos - cada comprimido recubierto contiene: ponatinib 15 mg (como ponatinib clorhidrato 16.03 mg)